# Socceromics: A Systematic Review of Omics Technologies to Optimize Performance and Health in Soccer

**Authors:** Adam Owen, Halil İbrahim Ceylan, Piotr Zmijewski, Carlo Biz, Giovanni Sciarretta, Alessandro Rossin, Pietro Ruggieri, Andrea De Giorgio, Carlo Trompetto, Nicola Luigi Bragazzi, Luca Puce

PMC · DOI: 10.3390/ijms27020749 · 2026-01-12

## TL;DR

This paper reviews how omics technologies like genomics and proteomics can help improve soccer player performance, recovery, and injury prevention through personalized strategies.

## Contribution

A systematic review of omics technologies in soccer, identifying specific genes and biological pathways linked to performance and injury risk.

## Key findings

- Genomic studies identified SNPs in genes like ACE, ACTN3, and COL1A1 linked to endurance, muscle performance, and injury risk.
- Proteomics, metabolomics, and microbiomics revealed biomarkers for muscle damage, fatigue, and gut health in soccer players.
- Omics data supports individualized training and recovery strategies tailored to players' biological profiles.

## Abstract

The integration of omics technologies, including genomics, proteomics, metabolomics, and microbiomics, has transformed sports science, particularly soccer, by providing new opportunities to optimize player performance, reduce injury risk, and enhance recovery. This systematic literature review was conducted in accordance with PRISMA 2020 guidelines and structured using the PICOS/PECOS framework. Comprehensive searches were performed in PubMed, Scopus, and Web of Science up to August 2025. Eligible studies were peer-reviewed original research involving professional or elite soccer players that applied at least one omics approach to outcomes related to performance, health, recovery, or injury prevention. Reviews, conference abstracts, editorials, and studies not involving soccer or omics technologies were excluded. A total of 139 studies met the inclusion criteria. Across the included studies, a total of 19,449 participants were analyzed. Genomic investigations identified numerous single-nucleotide polymorphisms (SNPs) spanning key biological pathways. Cardiovascular and vascular genes (e.g., ACE, AGT, NOS3, VEGF, ADRA2A, ADRB1–3) were associated with endurance, cardiovascular regulation, and recovery. Genes related to muscle structure, metabolism, and hypertrophy (e.g., ACTN3, CKM, MLCK, TRIM63, TTN-AS1, HIF1A, MSTN, MCT1, AMPD1) were linked to sprint performance, metabolic efficiency, and muscle injury susceptibility. Neurotransmission-related genes (BDNF, COMT, DRD1–3, DBH, SLC6A4, HTR2A, APOE) influenced motivation, fatigue, cognitive performance, and brain injury recovery. Connective tissue and extracellular matrix genes (COL1A1, COL1A2, COL2A1, COL5A1, COL12A1, COL22A1, ELN, EMILIN1, TNC, MMP3, GEFT, LIF, HGF) were implicated in ligament, tendon, and muscle injury risk. Energy metabolism and mitochondrial function genes (PPARA, PPARG, PPARD, PPARGC1A, UCP1–3, FTO, TFAM) shaped endurance capacity, substrate utilization, and body composition. Oxidative stress and detoxification pathways (GSTM1, GSTP1, GSTT1, NRF2) influenced recovery and resilience, while bone-related variants (VDR, P2RX7, RANK/RANKL/OPG) were associated with bone density and remodeling. Beyond genomics, proteomics identified markers of muscle damage and repair, metabolomics characterized fatigue- and energy-related signatures, and microbiomics revealed links between gut microbial diversity, recovery, and physiological resilience. Evidence from omics research in soccer supports the potential for individualized approaches to training, nutrition, recovery, and injury prevention. By integrating genomics, proteomics, metabolomics, and microbiomics data, clubs and sports practitioners may design precision strategies tailored to each player’s biological profile. Future research should expand on multi-omics integration, explore gene–environment interactions, and improve representation across sexes, age groups, and competitive levels to advance precision sports medicine in soccer.

## Linked entities

- **Genes:** ACE (angiotensin I converting enzyme) [NCBI Gene 1636], AGT (angiotensinogen) [NCBI Gene 183], NOS3 (nitric oxide synthase 3) [NCBI Gene 4846], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], ADRA2A (adrenoceptor alpha 2A) [NCBI Gene 150], ACTN3 (actinin alpha 3) [NCBI Gene 89], CKM (creatine kinase, M-type) [NCBI Gene 1158], MYLK (myosin light chain kinase) [NCBI Gene 4638], TRIM63 (tripartite motif containing 63) [NCBI Gene 84676], TTN-AS1 (TTN antisense RNA 1) [NCBI Gene 100506866], HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], MSTN (myostatin) [NCBI Gene 2660], CMA1 (chymase 1) [NCBI Gene 1215], AMPD1 (adenosine monophosphate deaminase 1) [NCBI Gene 270], BDNF (brain derived neurotrophic factor) [NCBI Gene 627], COMT (catechol-O-methyltransferase) [NCBI Gene 1312], DBH (dopamine beta-hydroxylase) [NCBI Gene 1621], SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532], HTR2A (5-hydroxytryptamine receptor 2A) [NCBI Gene 3356], APOE (apolipoprotein E) [NCBI Gene 348], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278], COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280], COL5A1 (collagen type V alpha 1 chain) [NCBI Gene 1289], COL12A1 (collagen type XII alpha 1 chain) [NCBI Gene 1303], COL22A1 (collagen type XXII alpha 1 chain) [NCBI Gene 169044], ELN (elastin) [NCBI Gene 2006], EMILIN1 (elastin microfibril interfacer 1) [NCBI Gene 11117], TNC (tenascin C) [NCBI Gene 3371], MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314], ARHGEF25 (Rho guanine nucleotide exchange factor 25) [NCBI Gene 115557], LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976], HGF (hepatocyte growth factor) [NCBI Gene 3082], PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465], PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468], PPARD (peroxisome proliferator activated receptor delta) [NCBI Gene 5467], PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891], FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068], TFAM (transcription factor A, mitochondrial) [NCBI Gene 7019], GSTM1 (glutathione S-transferase mu 1) [NCBI Gene 2944], GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950], GSTT1 (glutathione S-transferase theta 1) [NCBI Gene 2952], GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], VDR (vitamin D receptor) [NCBI Gene 7421], P2RX7 (purinergic receptor P2X 7) [NCBI Gene 5027]

## Full-text entities

- **Genes:** PPARD (peroxisome proliferator activated receptor delta) [NCBI Gene 5467] {aka FAAR, NR1C2, NUC1, NUCI, NUCII, PPARB}, TFAM (transcription factor A, mitochondrial) [NCBI Gene 7019] {aka MTDPS15, MTTF1, MTTFA, TCF6, TCF6L1, TCF6L2}, P2RX7 (purinergic receptor P2X 7) [NCBI Gene 5027] {aka P2X7}, GSTT1 (glutathione S-transferase theta 1) [NCBI Gene 2952], COL5A1 (collagen type V alpha 1 chain) [NCBI Gene 1289] {aka EDSC, EDSCL1, FMDMF}, NOS3 (nitric oxide synthase 3) [NCBI Gene 4846] {aka EC-NOS, ECNOS, MYMY8, NOSIII, cNOS, eNOS}, COL2A1 (collagen type II alpha 1 chain) [NCBI Gene 1280] {aka ACG2, ANFH, ANFH1, AOM, COL11A3, EDMMD}, SLC6A4 (solute carrier family 6 member 4) [NCBI Gene 6532] {aka 5-HTT, 5-HTTLPR, 5HTT, HTT, OCD1, SERT}, TRIM63 (tripartite motif containing 63) [NCBI Gene 84676] {aka CMH31, IRF, MURF1, MURF2, RNF28, SMRZ}, VDR (vitamin D receptor) [NCBI Gene 7421] {aka NR1I1, PPP1R163}, LIF (LIF interleukin 6 family cytokine) [NCBI Gene 3976] {aka CDF, DIA, HILDA, MLPLI}, HTR2A (5-hydroxytryptamine receptor 2A) [NCBI Gene 3356] {aka 5-HT2A, HTR2}, COL22A1 (collagen type XXII alpha 1 chain) [NCBI Gene 169044], ARHGEF25 (Rho guanine nucleotide exchange factor 25) [NCBI Gene 115557] {aka GEFT, p63RhoGEF}, HGF (hepatocyte growth factor) [NCBI Gene 3082] {aka DFNB39, F-TCF, HGFB, HPTA, SF}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277] {aka CAFYD, EDSARTH1, EDSC, OI1, OI2, OI3}, AGT (angiotensinogen) [NCBI Gene 183] {aka ANHU, SERPINA8, hFLT1}, MMP3 (matrix metallopeptidase 3) [NCBI Gene 4314] {aka CHDS6, MMP-3, SL-1, STMY, STMY1, STR1}, COL12A1 (collagen type XII alpha 1 chain) [NCBI Gene 1303] {aka BA209D8.1, BTHLM2, COL12A1L, DJ234P15.1, EDSMYP, UCMD2}, TNFSF11 (TNF superfamily member 11) [NCBI Gene 8600] {aka CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, CKM (creatine kinase, M-type) [NCBI Gene 1158] {aka CKMM, CPK-M, M-CK}, TTN-AS1 (TTN antisense RNA 1) [NCBI Gene 100506866], GSTP1 (glutathione S-transferase pi 1) [NCBI Gene 2950] {aka DFN7, FAEES3, GST3, GSTP, GSTP1-1, HEL-S-22}, GSTM1 (glutathione S-transferase mu 1) [NCBI Gene 2944] {aka GST1, GSTM1-1, GSTM1a-1a, GSTM1b-1b, GTH4, GTM1}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, DBH (dopamine beta-hydroxylase) [NCBI Gene 1621] {aka DBM, ORTHYP1}, BTF3P11 (basic transcription factor 3 pseudogene 11) [NCBI Gene 690] {aka BRF3L1, BTF3L1, HUMBTFB, OCIF, OPG, TNFRSF11B}, FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068] {aka ALKBH9, BMIQ14, GDFD, IFEX9}, TNC (tenascin C) [NCBI Gene 3371] {aka 150-225, DFNA56, GMEM, GP, HXB, JI}, SLC16A1 (solute carrier family 16 member 1) [NCBI Gene 6566] {aka HHF7, MCT, MCT1, MCT1D}, ACTN3 (actinin alpha 3) [NCBI Gene 89] {aka ACTN3D}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, AMPD1 (adenosine monophosphate deaminase 1) [NCBI Gene 270] {aka MAD, MADA, MMDD}, PPARA (peroxisome proliferator activated receptor alpha) [NCBI Gene 5465] {aka NR1C1, PPAR, PPAR-alpha, PPARalpha, hPPAR}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, MSTN (myostatin) [NCBI Gene 2660] {aka GDF8, MSLHP}, EMILIN1 (elastin microfibril interfacer 1) [NCBI Gene 11117] {aka ATBFS, EMI, EMILIN, HMN10, HMND10, gp115}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, AP2B1 (adaptor related protein complex 2 subunit beta 1) [NCBI Gene 163] {aka ADTB2, AP105B, AP2-BETA, CLAPB1}, MYLK3 (myosin light chain kinase 3) [NCBI Gene 91807] {aka MLCK, MLCK2, caMLCK}, PPARGC1A (PPARG coactivator 1 alpha) [NCBI Gene 10891] {aka LEM6, PGC-1(alpha), PGC-1alpha, PGC-1v, PGC1, PGC1A}, COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278] {aka EDSARTH2, EDSCV, OI4}, ADRA2A (adrenoceptor alpha 2A) [NCBI Gene 150] {aka ADRA2, ADRA2R, ADRAR, ALPHA2AAR, FPLD8}, COMT (catechol-O-methyltransferase) [NCBI Gene 1312] {aka HEL-S-98n}
- **Diseases:** brain injury (MESH:D001930), hypertrophy (MESH:D006984), ligament, tendon, and muscle injury (MESH:D013708), fatigue (MESH:D005221), muscle damage (MESH:D009133), muscle injury (MESH:D009135)

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12841393/full.md

---
Source: https://tomesphere.com/paper/PMC12841393